| REVIEW ARTICLE |
|
| Year : 2012 | Volume
: 9
| Issue : 1 | Page : 16-48 |
|
|
Antituberculosis therapy in patients with hepatitis B viral infection
Nikhil D Patel1, Shivaram Prasad Singh2
1 Jivandeep Hospital, Anand, Gujarat, India
2 Department of Gastroenterology, S.C.B. Medical College, Cuttack, India
Correspondence Address:
Nikhil D Patel
Jivandeep Hospital, Station Road, Anand - 388001, Gujarat
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0972-9747.193287
|
|
|
Tuberculosis (TB) and Hepatitis B virus (HBV) infections are quite common in the developing world especially South Asia. As both are so common, co-infection is not very uncommonly encountered in clinical practice. However, since anti-tuberculosis therapy (ATT) can be hepatotoxic in around 10% of patients, the occurrence of hepatotoxicity can complicate management especially in the presence of already compromised liver function due to HBV. Therefore, co-infection of TB and HBV is an important public health issue. Unfortunately the regional and National hepatology societies of South Asia have not bothered to provide any guidance in this matter. This article reviews the epidemiology and management of co-infection with Tuberculosis (TB) and Hepatitis B virus (HBV) and the hepatotoxicity due to ATT. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
